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Abstract
More than 10% of the population will suffer from a depressive disorder during their lifetime,
which represents a substantial economic and social burden for healthcare systems and
societies. Nonetheless, studies suggest that an important percentage of patients receive
inadequate treatment. This study aimed to evaluate the characteristics of patients with
depressive disorder in Spain, the current management of these disorders and the costs of
specialised care. A retrospective multicentre study was designed including admission rec-
ords from patients admitted due to a depressive disorder between 2011 and 2016, extracted
from a Spanish claims database. The records obtained corresponded to 306,917 patients
attended in primary care centres and 27,963 patients registered in specialised care settings.
The number of admissions per patient progressively increased over the study period. A cor-
relation was found with socioeconomic factors as the unemployment rate, increased versus
the general population (OR = 1.41; 95%CI = 1.38–1.43). Equally, comorbid conditions as
hypertension, disorders of lipoid metabolism, diabetes type II, other mood disorders and thy-
roid disorders were associated with severe presentations of a depressive disorder. In terms
of disease management, patients with a severe disorder were the majority in specialised
care settings, and most admissions were urgent and inpatient admissions. The use of both
electroconvulsive therapy and drug therapy increased during the study period. In terms of
costs, specialised care represented an annual cost of €9,654 per patient, and a total annual
cost of €44,839,196. Altogether, improved detection and treatment protocols could contrib-
ute in reducing the burden that depressive disorders represent for the Spanish National
Healthcare System.
Introduction
It is estimated that 4.4% of the global population suffer from a depressive disorder, with more
than 40 million people in Europe affected [1]. In Spain the estimated prevalence of major
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depressive disorder (MDD) was 8.0% among women and 4.1% among men in 2018 [2]; how-
ever, the average lifetime prevalence is estimated to reach the 10.6%, a percentage that is drasti-
cally increased in vulnerable groups as the hospitalised population [3, 4].
Mental illness represents substantial social and economic costs, as it is associated with dis-
ability and reduced quality of life [5–7]. The year 2016, these disorders were responsible for
6.43% of all disability-adjusted life-years (DALYs), and depression continues to be considered
the leading cause of disability worldwide [8, 9]. Major depressive disorder alone summed
about €155 million in direct medical costs in the region of Catalonia the year 2006, reaching
the €735 million when lost productivity due to morbidity and mortality are considered [10].
Despite the significant social and economic burden of depressive disorders, several studies
suggest that an important percentage of patients receive inadequate treatment and that the
adherence to guidelines is seemingly low [11], although improved treatment protocols have
been proven useful in decreasing the economic burden associated to these disorders [12].
The implementation of improved treatment protocols and specific guidelines is decisive for
the optimisation of healthcare in mental illness. Treatment options include pharmacological
therapy and physiological intervention, used in accordance with the severity of the symptoms
and other factors and often through various stages of treatment [13]. Current clinical guide-
lines in Spain were conformed via the revision of multiple international guidelines and primar-
ily based on the National Collaborating Centre for Mental Health (NCCMH) depression
treatment and management guideline [14]. These guidelines specify diagnosis criteria and
treatment options for the diverse presentations of depression, classifying treatment options in
physiotherapy and drug therapy, and considering other options, as electroconvulsive therapy,
for the treatment of severe disorders or treatment-resistant depression [15, 16]. Yet, the man-
agement of these disorders is seemingly not optimised, as data suggests that the percentage of
patients receiving inadequate treatment is especially significant in primary care, which is the
first level of care that meets the most basic health care needs, and around 71% of patients
could seek help exclusively in primary care settings without being admitted in specialised care
centres (hospitals) [11, 17].
This study aimed to evaluate the characteristics of patients with depressive disorders in
Spain admitted in primary and specialised care centres, current disease management and the
costs of specialised care, in an effort to provide a basis for the improvement of treatment guide-
lines for specialised care and, thus, the reduction of the burden related to these disorders.
Methods
Admission records of patients admitted in primary and specialised care centres with a primary
diagnosis of depression (admission motive) between 2011 and 2016 were extracted from a
Spanish claims database, compiling data from public and private healthcare centres, in a retro-
spective multicentre study. The code P76 from The International Classification of Primary
Care, second edition (ICPC-2) corresponding to depressive disorder was used to extract
admission records from primary care facilities (Table 1). The 9th and 10th revisions of the
International Statistical Classification of Diseases and Related Health Problems, Clinical Modi-
fication (ICD9-CM and ICD10-CM) codes were used to claim inpatient and outpatient care
records from specialised care facilities (hospitals), corresponding to major depressive disorder
with a single episode, recurrent depressive disorder and depressive disorders left unspecified;
until 2015 data was codified using ICD9 codes while since 2016 ICD10 codes are used.
All admission files were used to analyse data on the nature of admissions, medical proce-
dures and costs; for the analysis of patients’ characteristics solely the first admission registered
per patient during the study period was included. Medical procedures were determined via
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ICD, Procedure Classification System (ICD9-PCS and ICD10-PCS) codes. To ensure consis-
tency, tendencies in procedure utilisation were analysed solely via ICD9-PCS codes (2011–
2015). Specialised healthcare costs were calculated based on the standardised average expenses
of admissions and medical procedures determined by the Spanish Ministry of Health, which
includes all expenses related to the admission: examination, medication, surgery, nutrition,
costs associated to personnel, medical equipment and resources. Data related to the prescribed
medication was not available.
The data extracted did not contain any parameters identifying healthcare centres and medi-
cal history, which are re-coded in the database maintaining records anonymised, in accor-
dance with the principles of Good Clinical Practice and the Declaration of Helsinki. This
research did not involve human participants and there was no access to identifying informa-
tion; in this context the Spanish legislation does not require patient consent and ethics com-
mittee approval [18].
Data presentation is mainly descriptive. Descriptive values are presented in mean (SD). To
assess the association with any socioeconomic factors odds ratio (OR) with 95% confidence
interval (CI) were used, with the total population attended in primary care as reference group.
The population without mention of severe MDD was used as a reference when indicated [19].
Statistical analyses were performed using Microsoft Excel Professional Plus 2010 (Microsoft
Corporation, Redmond, WA, USA).
Results
Primary care
The 937,575 admissions registered in primary care corresponded to 306,917 patients. In a tem-
poral analysis, a progressive increase in the number of admissions per patient was observed,
up to the 6.69 admissions per patient registered in 2016.
Table 1. Depressive disorders identified according to ICPC-2, ICD9-CM and ICD10-CM codes and number of admissions registered per each disorder.
Primary care ICPC-2 (2011–16) Admission number
Depressive disorder P76 937,575
Specialised care ICD9 (2011–15) ICD10 (2016) Admission number
Major depressive disorder, single episode 296.2 F32 13,136
Mild 296.21 F32.0 307
Moderate 296.22 F32.1 2,063
Severe, without mention of psychotic behaviour 296.23 F32.2 1,931
Severe, specified as with psychotic behaviour 296.24 F32.3 3,142
In partial or unspecified remission 296.25 F32.4 121
In full remission 296.26 F32.5 19
Unspecified 296.20 F32.9 5,553
Recurrent major depressive disorder 296.3 F33 14,912
Mild 296.31 F33.0 251
Moderate 296.32 F33.1 1,940
Severe, without mention of psychotic behaviour 296.33 F33.2 3,241
Severe, specified as with psychotic behaviour 296.34 F33.3 3,495
In partial or unspecified remission 296.35 F33.40/41 756
In full remission 296.36 F33.42 33
Unspecified 296.30 F33.9 5,196
Depressive disorder, not elsewhere classified 311 F32/F33.8 8,201
https://doi.org/10.1371/journal.pone.0228749.t001
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Overall, 71.9% of the patients were females, with an average age of 57.69 years (SD = 17.92).
Male patients were slightly younger averaging 54.83 years (SD = 17.80).
Socioeconomic data extracted from primary care records revealed an increased presence of
patients with an annual income level under the €18,000, 77.43% of patients with a specified
income level belonged to this group (OR = 1.03; 95%CI = 1.02–1.03); 20.92% of patients were
between the €18,000 and the €99,999 (OR = 0.89; 95%CI = 0.88–0.90). The global unemploy-
ment rate throughout the study period was also increased versus the general population
(OR = 1.41; 95%CI = 1.38–1.43).
Specialised care
Admission records corresponded to 27,963 patients attended in specialised care settings;
11,107 were admitted with a single episode major depressive disorder and 9,647 with recurrent
major depressive disorder. In addition, 7,209 patients were registered with an unspecified
depressive disorder. Most of the patients attended in specialised care with a specified disorder
were labelled as severe (Fig 1). According to ICD classification, when considering the complete
patients’ history, 33.22% of patients entered remission at some point during the study period.
Herein, 59.97% of patients admitted with a depression disorder were females, a smaller per-
centage than in primary care; yet, female patients were more than 50% in all groups with a
specified disorder.
The mean age of patients attended in specialised care was 52.70 years (SD = 17.94); no rele-
vant fluctuations were found over the years. Equally, male and female patients displayed, on
average, a similar age, although males with a single episode MDD in remission were younger.
Primary diagnosis or admission motive was, in all cases, a depressive disorder; however,
specialised care records included secondary diagnoses registered during the admission. Hyper-
tension and disorders of lipoid metabolism (hypercholesterolaemia, hyperlipidaemia and
hyperglyceridaemia) were the most common conditions (Table 2). Several conditions were
more frequent in patients with severe MDD versus those without severe MDD, as hyperten-
sion, diabetes, lipoid disorders and thyroid disorders. The frequency of suicidal ideation and
suicide attempts was also increased in this group, although the difference versus the patients
without severe MDD was relatively small. Contrarily, drug abuse was registered in 4.26% of
Fig 1. Number of male and female patients admitted in specialised care with: A) a single episode MDD or B) a recurrent MDD.
https://doi.org/10.1371/journal.pone.0228749.g001
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patients with severe MDD, 4.93% of those without MDD. When analysed independently,
patients that attempted suicide displayed similar secondary diagnoses, but a higher rate of
alcohol abuse (17.61%; OR = 1.64; 95%CI = 1.42–1.90).
In addition, records offered a clear view of disease management. The 86.64% of all special-
ised care admissions were urgent; 414 admissions corresponded to outpatient consultations
versus 35,835 inpatient admissions. In this last case, mean length of hospital stay was 16.90
days, 22.80 days in patients with severe MDD and 14.05 days in those without severe MDD.
Readmission rate within 30 days was 8.12% in patients with a single episode disorder and
16.99% in patients with a recurrent disorder, while it was 15.63% and 14.04% in patients with
severe MDD and those without mention of severe MDD respectively. The service to discharge
the most patients was psychiatry (91.78%).
The most common medical procedures could be classified in several categories, according
to their ICD9-PCS and ICD10-PCS codes, as: psychiatric somatotherapy, psychiatric inter-
views, consultations and evaluations, individual psychotherapy, referral for psychological reha-
bilitation, psychological evaluation and testing and general diagnostic tests and imaging
(Table 3). Patients with severe MDD registered higher rates of drug therapy (OR = 3.72; 95%
CI = 3.51–3.94), while such difference was not registered in the use of electroconvulsive ther-
apy. Overall, psychiatric somatotherapy was the most common therapy for all patients and its
use increased from the 41.93% to the 56.87% between 2011 and 2015 due to the increase of
both electroconvulsive therapy and drug therapy (Fig 2).
Finally, admission records were associated to a cost per admission, providing an
approximation to the direct medical cost of depressive disorders. Altogether, each patient
represented an average annual cost of €9,654 for the healthcare system, considering that
96.28% of patients were financed by the social security system. In patients with a recurrent
MDD, this cost increases to €9,947. Equally, patients with severe MDD represented an
annual cost of €10,883 per patient, whereas this figure in patients without severe MDD
was €9,094.
When analysed per years, the progressive increase in the number of admissions is visible as
a gradual increase of healthcare costs, especially noticeable between the years 2012 and 2013
(Fig 3). Nonetheless, the cost of patients with MDD peaks the year 2013 and slightly decreases
the following years.
With all admissions considered, the annual cost of specialised care of depressive disorders
in Spain was €44,839,196.
Table 2. Secondary diagnoses found in more than 5% of all patients admitted with or without severe MDD.
Secondary diagnoses % Severe MDD % Without severe MDD Odds Ratio a (95%CI)
Unspecified essential hypertension 29.59 17.68 1.96 (1.85–2.10)
Suicidal ideation 17.89 16.60 1.10 (1.01–1.19)
Disorders of lipoid metabolism 21.70 13.83 1.73 (1.60–1.86)
Tobacco use disorder 15.39 13.84 1.13 (1.04–1.23)
Alcohol abuse 9.63 11.08 0.85 (0.77–0.95)
Diabetes mellitus type II 14.49 8.98 1.72 (1.57–1.88)
Other mood disorders 8.81 7.73 1.15 (1.04–1.29)
Thyroid disorders 10.24 6.44 1.66 (1.49–1.84)
Suicide 6.29 4.93 1.29 (1.14–1.47)
a Odds ratio for diagnosis frequency, patients with severe MDD vs. without severe MDD.
https://doi.org/10.1371/journal.pone.0228749.t002
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Table 3. Medical procedures found in more than 1% of admissions of all patients admitted with or without severe MDD.
Medical procedure % Severe MDD % Without severe MDD Odds Ratio a
(95%CI)
Psychiatric somatotherapy 70.95 41.64 3.42 (3.25–3.60)
Electroconvulsive therapy 22.87 21.81 1.06 (1.00–1.13)
Psychiatric drug therapy 37.67 13.97 3.72 (3.51–3.94)
Neuroleptic therapy 8.50 5.11 1.72 (1.57–1.90)
Psychiatric interviews, consultations, evaluations 32.45 31.02 1.07 (1.01–1.13)
Other psychiatric interview and evaluation 14.20 15.33 0.91 (0.85–0.98)
Psychiatric mental status determination 12.26 9.87 1.28 (1.18–1.38)
Psychiatric commitment evaluation 4.37 4.37 1.00 (0.89–1.13)
Individual psychotherapy 7.39 10.12 0.71 (0.65–0.77)
Other psychotherapy and counselling 3.55 5.96 0.58 (0.51–0.66)
Other individual psychotherapy 3.10 4.38 0.70 (0.61–0.80)
Supportive verbal psychotherapy 1.44 2.54 0.56 (0.46–0.68)
Crisis intervention 1.96 2.11 0.93 (0.78–1.10)
Referral for psychological rehabilitation 1.95 2.65 0.73 (0.62–0.86)
Referral for psychiatric aftercare 1.88 2.24 0.83 (0.70–0.99)
Physiological evaluation and testing 2.05 1.48 1.39 (1.16–1.67)
Diagnostic tests - - -
Microscopic examination of blood/urine 15.34 18.45 0.80 (0.75–0.86)
Diagnostic imaging of head and brain 22.09 15.00 1.61 (1.51–1.71)
Diagnostic imaging of chest and abdomen 8.08 9.75 0.81 (0.75–0.89)
Diagnostic ultrasound of heart/ electrocardiogram 7.60 8.77 0.86 (0.78–0.94)
Injection of antibiotic or therapeutic substance 4.20 4.68 0.89 (0.79–1.00)
a Odds ratio for diagnosis frequency, patients with severe MDD vs. without severe MDD.
https://doi.org/10.1371/journal.pone.0228749.t003
Fig 2. Changes registered in procedure utilisation over time (2011–2015).
https://doi.org/10.1371/journal.pone.0228749.g002
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Discussion
The high prevalence and substantial social and economic burden of depressive disorders con-
trasts with the insufficient detection of these disorders in primary care and the inadequate
treatment received by many patients. This study describes the current status of depressive dis-
orders in Spain, in terms of patient characteristics, disease management and its costs.
The patient profile described in this study is comparable to previous evaluations. The
increased percentage of female patients in primary care settings has been previously described
in Spain [11, 20]. On average, the patients that access specialised care are slightly younger and
are mostly diagnosed with a severe disorder, which is not surprising given the low detection
rate of mild forms of depression [21].
The association of depressive disorders with socioeconomic indicators is apparent in
patients’ unemployment rate, increased versus the general population. The portion of patients
with an income level under €18,000 was also increased, strengthening the evidence linking
these factors with depression [22, 23]. All evidence suggests that detection protocols should
consider socioeconomic indicators to establish risk groups, a practice that is currently not into
consideration in Spain [15, 16]. Equally, the presence of certain comorbid conditions found in
patients with depressive disorder and, at a higher rate, in patients with a severe disorder should
be taken into account, particularly those described in previous assessments, as are the
increased levels of triglycerides and cholesterol or the presence of type II diabetes [24, 25].
Additionally, there is strong evidence linking thyroid disorders, especially hypothyroidism,
with depression [26, 27], which herein correlate with the severity of the MDD. Alcohol abuse
appeared associated to suicide and should be considered one of the risk factors for suicide in
patients with depression also within the Spanish population [28].
Currently, most patients with depressive disorders in Spain are attended in primary care, as
considering the number of admissions registered in primary care settings versus specialised
Fig 3. Annual medical costs of specialised care of depressive disorders considering all patients, patients with MDD and patients without MDD.
https://doi.org/10.1371/journal.pone.0228749.g003
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care. The number of admissions per patient increased during the study period in primary care,
which indicates the need for successive consultations. In specialised care, most of the admis-
sions were urgent and hospitalisation was required. Interestingly, the use of electroconvulsive
therapy increased over time in parallel with drug therapy, although it is only recommended for
the treatment of severe and resistant disorders [15]. A study from 2012 based on a question-
naire showed that 84.2% of psychiatric units prescribed electroconvulsive therapy, a percent-
age that grew considerably since 2001, with great variation among Spanish regions [29]. These
data indicated the need to unify criteria for the application of this therapy alternative, while
current recommendations focus on the flexibility and adaptability of its application to reduce
side effects [30], still, psychotherapy is preferred in the mildest cases of the disorder [15, 16].
In terms of costs, evaluations at the European level estimated a cost of specialised care that
represented 8.5% of all direct medical costs, while primary care summed 18.6% of the costs
and pharmacological care the 7.6% [5]. Herein, specialised care summed €44,839,196 per year,
costs that, added to primary and pharmacological care, could increase to about €529 million.
In addition, the productivity losses due to disability and mortality contribute to increase the
burden of depressive disorders [8, 9]. More effective detection and treatment protocols, espe-
cially in primary care and for patients with recurrent MDD, could contribute in reducing this
burden. Our analysis of annual costs and their evolution suggests a decrease in the annual cost
per patient after the year 2013, noticeable for patients with severe MDD, which could be indic-
ative of changes in the in-hospital treatment that these patients receive.
The conclusions of this study were subjected to a series of limitations. Firstly, the costs of
primary care and prescribed medication could not be directly calculated via this database. Sec-
ondly, primary care records do not include disease management data, which impedes a more
consistent analysis of treatment preferences and deficiencies, particularly in patients with mild
disorders. Finally, data obtained in this study should be considered in the context of character-
ising the population that is hospitalised due to MDD and is not translatable to the entire popu-
lation affected with depression that might present different associated conditions.
Conclusions
Depressive disorders continue to represent a substantial burden for the Spanish National
Healthcare System, reaching the €44,839,196 solely in specialised healthcare. The improve-
ment of treatment protocols, taking into account socioeconomic risk factors and the presence
of associated conditions, should contribute in reducing this burden while focusing in a more
flexible and personalised treatment. In particular, depression management in primary care
centres should be optimised as these settings attend the major portion of patients.
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19. Portal Estadı́stico, Área de Inteligencia de Gestión: Base de datos de Clı́nicos de Atención Primaria
(BDCAP) [Internet]. Madrid: Ministerio de Sanidad, Gobierno de España, 2019 [cited 2019 Oct 11].
Available from: https://pestadistico.inteligenciadegestion.mscbs.es/publicoSNS/comun/ArbolNodos.
aspx?idNodo=22117.
20. Muñoz-Navarro R, Cano-Vindel A, Medrano LA, Schmitz F, Ruiz-Rodrı́guez P, Abellán-Maeso C, et al.
Utility of the PHQ-9 to identify major depressive disorder in adult patients in Spanish primary care cen-
tres. BMC Psychiatry. 2017 Aug 9; 17(1):291. https://doi.org/10.1186/s12888-017-1450-8 PMID:
28793892
21. Aragonès E, Piñol JL, Labad A, Folch S, Mèlich N. Detection and management of depressive disorders
in primary care in Spain. Int J Psychiatry Med. 2004; 34(4):331–43. https://doi.org/10.2190/N835-
FDYX-2E2E-V8XM PMID: 15825583
22. Zuelke AE, Luck T, Schroeter ML, Witte AV, Hinz A, Engel C, et al. The association between unemploy-
ment and depression-Results from the population-based LIFE-adult-study. J Affect Disord. 2018 Aug 1;
235:399–406. https://doi.org/10.1016/j.jad.2018.04.073 PMID: 29677604
23. Latsou D, Geitona M. The Effects of Unemployment and Economic Distress on Depression Symptoms.
Mater Sociomed. 2018 Oct; 30(3):180–84. https://doi.org/10.5455/msm.2018.30.180-184 PMID:
30515055
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